Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

EPT Disclosure

9 Oct 2008 09:26

RNS Number : 4603F
Liberum Capital Limited
09 October 2008
 
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
 
 
1. KEY INFORMATION
 
Name of exempt principal trader
Liberum Capital Limited
Company dealt in
Flying Brands
Class of relevant security to which the dealings being disclosed relate(Note 1)
Units comprising 1 ordinary 1p share and 1 A ordinary of 0.005p share
Date of dealing
08/10/08
 
 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
 
 
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
26,125 0.001%
0 0%
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
26,125 0.001%
0 0%
 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
 
Class of relevant security:
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
 
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
 
 
 
(c) Rights to subscribe (Note 2)
 
Class of relevant security:
 
Details
 
 
 
3. DEALINGS (Note 3)
 
(a) Purchases and sales
 
Purchase/sale
 
Number of securities
Price per unit (Note 4)
Purchase
1,114
0.435p
 
 
 
 
 
 
 
 
 
(b) Derivatives transactions (other than options)
 
Product name,
e.g. CFD
Long/short (Note 5)
Number of securities (Note 6)
Price per unit (Note 4)
 
 
 
 
 
 
 
 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
 
Product name,
e.g. call option
 
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 6)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 4)
 
 
 
 
 
 
 
 
 
(ii) Exercising
 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 4)
 
 
 
 
 
 
(d) Other dealings (including new securities) (Note 3)
 
Nature of transaction (Note 7)
 
Details
Price per unit (if applicable)(Note 4)
 
 
 
 
 
 
 
 
 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 
 
None
 
 
 
Is a Supplemental Form 38.5(b) attached? (Note 8) NO
 
 
Date of disclosure
09/10/08
Contact name
Carl Chambers
Telephone number
020 3100 2000
Name of offeree/offeror with which connected
West Coast Capital
Nature of connection (Note 9)
Adviser
 
 
Notes
 
The Notes on Form 38.5(b) can be viewed on the Takeover Panel’s website at www.thetakeoverpanel.org.uk
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMFSISAUSASEES
Date   Source Headline
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20212:05 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 20219:05 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNS"Gad Free" Imaging Update
25th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSTechnology Portfolio Update
7th Jan 20212:06 pmRNSSecond Price Monitoring Extn
7th Jan 20212:00 pmRNSPrice Monitoring Extension
31st Dec 202012:41 pmRNSSecond Price Monitoring Extn
31st Dec 202012:36 pmRNSPrice Monitoring Extension
31st Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 202010:41 amRNSDirector Dealing and CLN Conversion - Correction
9th Dec 20202:05 pmRNSSecond Price Monitoring Extn
9th Dec 20202:01 pmRNSPrice Monitoring Extension
9th Dec 20209:02 amRNSDirector Dealing and Conversion of Loan Notes
7th Dec 202011:25 amRNSDirector Dealing
4th Dec 20204:52 pmRNSIssue of shares to Mayo Clinic
3rd Dec 20207:01 amRNSRelease of StoneChecker 20.12
26th Nov 20207:00 amRNSIMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE
23rd Nov 20204:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20202:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20202:00 pmRNSPrice Monitoring Extension
23rd Nov 20201:45 pmRNSLSN Software is now CE Mark Approved
23rd Nov 202011:06 amRNSSecond Price Monitoring Extn
23rd Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 202011:05 amRNSSecond Price Monitoring Extn
20th Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.